Cytek Biosciences, Inc.
CTKB
$4.10
-$0.07-1.68%
NASDAQ
| 06/30/2025 | 03/31/2025 | ||||
|---|---|---|---|---|---|
| Revenue | 10.00% | -27.87% | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | 10.00% | -27.87% | |||
| Cost of Revenue | 2.04% | -10.59% | |||
| Gross Profit | 18.41% | -40.10% | |||
| SG&A Expenses | 1.02% | 7.92% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | -0.37% | -1.15% | |||
| Operating Income | 29.06% | -3,979.53% | |||
| Income Before Tax | 39.86% | -209.13% | |||
| Income Tax Expenses | -976.47% | -80.00% | |||
| Earnings from Continuing Operations | 51.03% | -218.24% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | 51.03% | -218.24% | |||
| EBIT | 29.06% | -3,979.53% | |||
| EBITDA | 33.33% | -684.82% | |||
| EPS Basic | 50.45% | -218.88% | |||
| Normalized Basic EPS | 39.16% | -246.79% | |||
| EPS Diluted | 51.11% | -226.23% | |||
| Normalized Diluted EPS | 39.16% | -246.79% | |||
| Average Basic Shares Outstanding | -1.09% | -0.57% | |||
| Average Diluted Shares Outstanding | -1.09% | -0.57% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||